Needham, MA-based Celldex Therapeutics (NASDAQ: [[ticker:CLDX]]) said it has received a $10 million milestone payment triggered by the U.S. launch of the oral rotavirus vaccine Rotarix, which is marketed by GlaxoSmithKline (NYSE: [[ticker:GSK]]). Celldex was formed through the recent merger of Avant Immunotherapeutics of Needham and Phillipsburg, NJ-based Celldex Therapeutics.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
